春立医疗 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	806.0M	1.2B	1.2B	1.1B	938.0M
Revenue Growth %	-33.3%	0.6%	8.5%	18.1%	--
Total Revenue	806.0M	1.2B	1.2B	1.1B	938.0M
Cost Of Revenue	269.0M	333.0M	288.0M	254.0M	257.0M
+Gross Profit	537.0M	876.0M	914.0M	854.0M	681.0M
Gross Margin %	66.6%	72.5%	76.0%	77.1%	72.6%
Total Operating Cost	716.0M	937.0M	904.0M	758.0M	616.0M
Selling Expenses	240.0M	383.0M	391.0M	342.0M	241.0M
Admin Expenses	45.3M	44.5M	38.8M	30.7M	31.2M
Rd Expenses	133.0M	157.0M	162.0M	105.0M	72.6M
Finance Expenses	-17.1M	-16.6M	-20.2M	-9.6M	-1.6M
+Operating Income	131.0M	306.0M	329.0M	368.0M	330.0M
Operating Margin %	16.3%	25.3%	27.4%	33.2%	35.2%
Non Operating Income	987,400	346,900	10.3M	138,900	765,300
Non Operating Expenses	102,900	416,500	2.3M	351,900	1.0M
Investment Income	11.0M	12.0M	6.7M	--	--
Fair Value Change Income	9.4M	9.6M	9.5M	--	--
Asset Disposal Income	39,200	3,900	25,300	14,900	-158,200
Asset Impairment Loss	33.8M	20.7M	13.5M	10.5M	158,100
Other Income	20.6M	12.8M	15.2M	17.5M	8.4M
Income Before Tax	132.0M	306.0M	337.0M	367.0M	330.0M
Income Tax	6.9M	28.1M	29.2M	45.0M	46.5M
+Net Income	125.0M	278.0M	308.0M	322.0M	283.0M
Net Margin %	15.5%	23.0%	25.6%	29.1%	30.2%
Net Income Attributable	125.0M	278.0M	308.0M	322.0M	283.0M
Minority Interest	-326,700	-5,900	--	--	--
Eps Basic	0.33	0.72	0.80	0.93	0.82
Eps Diluted	0.33	0.72	0.80	0.93	0.82

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	1.1B	1.3B	957.0M	1.7B	690.0M
Trading Financial Assets	746.0M	832.0M	768.0M	--	--
Accounts Receivable	219.0M	406.0M	489.0M	400.0M	221.0M
Notes Receivable	160.0M	35.8M	279.0M	128.0M	150.0M
Notes And Accounts Receivable	379.0M	442.0M	767.0M	528.0M	371.0M
Prepayments	3.0M	10.8M	12.7M	7.7M	10.5M
Inventory	551.0M	434.0M	260.0M	160.0M	169.0M
Total Current Assets	2.8B	3.0B	2.8B	2.4B	1.3B
Fixed Assets	--	313.0M	278.0M	111.0M	108.0M
Fixed Assets Total	311.0M	313.0M	278.0M	111.0M	108.0M
Construction In Progress	--	150.0M	185.0M	282.0M	55.1M
Construction In Progress Total	157.0M	150.0M	185.0M	282.0M	55.1M
Intangible Assets	128.0M	136.0M	138.0M	132.0M	101.0M
Long Term Deferred Expenses	--	--	--	128,300	348,300
Total Non Current Assets	625.0M	644.0M	631.0M	552.0M	290.0M
Total Assets	3.5B	3.6B	3.4B	3.0B	1.5B
Accounts Payable	228.0M	226.0M	238.0M	142.0M	90.3M
Advance Receipts	--	--	--	7.0M	7.9M
Contract Liabilities	129.0M	150.0M	85.7M	59.5M	82.9M
Total Current Liabilities	547.0M	677.0M	596.0M	440.0M	369.0M
Total Non Current Liabilities	97.6M	93.7M	94.3M	91.0M	93.4M
Total Liabilities	644.0M	770.0M	690.0M	531.0M	462.0M
Paid In Capital	384.0M	384.0M	384.0M	384.0M	346.0M
Capital Reserve	1.0B	1.0B	1.1B	1.1B	22.5M
Surplus Reserve	195.0M	182.0M	155.0M	125.0M	92.4M
Retained Earnings	1.2B	1.3B	1.1B	909.0M	619.0M
Minority Equity	1.4M	1.8M	--	--	--
Equity Attributable	2.8B	2.9B	2.7B	2.5B	1.1B
Total Equity	2.8B	2.9B	2.7B	2.5B	1.1B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	898.0M	1.6B	903.0M	956.0M	901.0M
Tax Refunds Received	12.1M	--	--	--	--
Total Operating Cash Inflow	954.0M	1.7B	932.0M	973.0M	928.0M
Cash Paid For Goods	358.0M	409.0M	247.0M	198.0M	168.0M
Cash Paid To Employees	247.0M	234.0M	193.0M	143.0M	121.0M
Taxes Paid	75.4M	96.3M	101.0M	142.0M	148.0M
Total Operating Cash Outflow	956.0M	1.1B	891.0M	808.0M	667.0M
Operating Cash Flow	-1.9M	512.0M	41.0M	165.0M	261.0M
Total Investing Cash Inflow	2.4B	2.4B	1.4B	9.1M	2.5M
Total Investing Cash Outflow	2.3B	2.4B	2.2B	199.0M	24.0M
Investing Cash Flow	55.8M	-81.6M	-763.0M	-190.0M	-21.5M
Dividends And Interest Paid	171.0M	120.0M	50.0M	--	11.9M
Total Financing Cash Inflow	--	--	--	1.1B	--
Total Financing Cash Outflow	183.0M	121.0M	59.0M	2.2M	11.9M
Financing Cash Flow	-183.0M	-121.0M	-59.0M	1.1B	-11.9M
Net Change In Cash	-127.0M	309.0M	-779.0M	1.0B	226.0M
Ending Cash Balance	1.1B	1.3B	957.0M	1.7B	690.0M
Capex	49.2M	33.2M	24.9M	199.0M	24.0M